(Reuters) – The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed Medicare coverage of approved CAR-T cell therapies that use the patient’s immune system to fight cancer.
The proposal would require Medicare to cover the therapy nationwide when it is offered in a CMS-approved registry or clinical study, in which patients are monitored for at least two years post-treatment, CMS said.
The evidence from these studies and registries would help the agency identify the patients that benefit from CAR-T cell therapies.
“Today’s proposed coverage decision would improve access to this therapy while deepening CMS’s understanding of how patients in Medicare respond to it,” CMS Administrator Seema Verma said in a statement.
Chimeric antigen receptor T-cell therapy, known as CAR-T, harnesses the body’s own immune cells to recognize and attack malignant cells.
Approved CAR-T therapies include Novartis AG’s Kmyriah treatment for leukemia and Gilead Sciences Inc’s Yescarta.
Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur